ClinicalTrials.gg
CompletedNCT04026412CheckMate73LUpdated Jul 24, 2025Results posted

A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery

A Phase 3 interventional study of nivolumab and ipilimumab in Non-Small Cell Lung Cancer (NSCLC), sponsored by Bristol-Myers Squibb. Completed at 183 sites in 27 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-24.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
925
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung — 22 open to participants now, 44 under way, 6 of them phase 3. Nivolumab · Carcinoma, Non-Small-Cell Lung.

Enrollment
5th of 120
925 · median 66
Started
2019
with 8 others
Phase 3
24 of 120
3 open now
Registered
78th of 120
by date
Lead sponsor
28 of 120
Bristol-Myers Squibb

Among the 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung, this one is the 5th largest by enrollment, is one of 9 that started in 2019, is one of 24 in phase 3, and was the 78th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

22 of the 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

17 more — sign in →

By country, each count listing its studies:

All 22 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The primary purpose of the study is to compare the effectiveness of nivolumab plus concurrent chemoradiotherapy (CCRT) followed by nivolumab plus ipilimumab vs CCRT followed by durvalumab in participants with untreated Locally Advanced Non-small Cell Lung Cancer (LA NSCLC).

03

Conditions studied

  • Non-Small Cell Lung Cancer (NSCLC)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (ECOG) performance status ≤1
  • Locally advanced stage IIIA, IIIB, or IIIC (T1-2 N2-3 M0, T3 N1-3 M0, or T4 N0-3 M0) -confirmed NSCLC, according to 8th TNM classification. Participants who are not planned for potential curative surgical resection are eligible.
  • Newly diagnosed and treatment-naïve, with no prior local or systemic anticancer therapy given as primary therapy for locally advanced disease

Exclusion criteria

Exclusion Criteria:

  • Any condition including medical, emotional, psychiatric, or logistical that, in the opinion of the Investigator would preclude the participant from adhering to the protocol or would increase the risk associated with study participation
  • Active infection requiring systemic therapy within 14 days prior to randomization
  • History of organ or tissue transplant that requires systemic use of immune suppressive agents
  • Prior thoracic radiotherapy

Other protocol-defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
925 participants (actual)

Study arms

  • Experimental
    Arm A: nivolumab + CCRT + ipilimumab

    Concurrent chemoradiotherapy (CCRT)

    Biological: nivolumab · Biological: ipilimumab

  • Experimental
    Arm B: nivolumab + CCRT

    Concurrent chemoradiotherapy (CCRT)

    Biological: nivolumab

  • Experimental
    Arm C: CCRT + durvalumab

    Concurrent chemoradiotherapy (CCRT)

    Biological: durvalumab

Interventions

  • Biologicalnivolumab

    Specified dose on specified days

  • Biologicalipilimumab

    Specified dose on specified days

  • Biologicaldurvalumab

    Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Arm A Vs Arm C - Progression-Free Survival (PFS) by RECIST 1.1 Per Blinded Independent Central Review (BICR)

    Progression-Free Survival then (PFS) is defined as the time between the date of randomization and the date of first documented disease progression, based on BICR assessments (per RECIST v1.1), or death due to any cause, whichever occurs first based on Kaplan-Meier estimates. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

    Time frame: From randomization untill disease progression or death, whichever occurs first (up to approximately 53 months)

Secondary outcomes

  1. Overall Survival (OS)

    Overall Survival (OS) for all randomized participants is the time between randomization and the date of death from any cause based on Kaplan-Meier estimates. For participants who are alive, their survival time was censored at the last date that they were known to be alive. OS was censored for participants at the date of randomization if they had no follow-up.

    Time frame: From randomization untill death (up to approximately 61 months)

  2. Arm B Vs Arm C and Arm A Vs Arm B- Progression-Free Survival (Irrespective of Subsequent Therapy) by RECIST 1.1 Per Blinded Independent Central Review (BICR)

    Progression-Free Survival (PFS) is defined as the time between the date of randomization and the date of first documented disease progression, based on BICR assessments (per RECIST v1.1), or death due to any cause, whichever occurs first based on Kaplan-Meier estimates. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

    Time frame: From randomization untill disease progression or death, whichever occurs first (up to approximately 61 months)

  3. Objective Response Rate (ORR) by BICR

    Objective Response Rate (ORR) is defined as the percentage of participants whose best overall response (BOR) is either CR or PR by blinded independent central review (BICR) per response evaluation criteria in solid tumors (RECIST) v1.1. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

    Time frame: From randomization untill disease progression or death, whichever occurs first (up to approximately 61 months)

  4. Duration of Response (DoR) by RECIST 1.1 Per BICR

    Duration of objective response (DoR) is defined as the time between the date of first confirmed response (CR or PR) to the date of the first documented tumor progression (per RECIST 1.1) per BICR assessment, or death due to any cause, whichever occurs first. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

    Time frame: From randomization untill disease progression or death, whichever occurs first (up to approximately 61 months)

  5. Time to Response (TTR) by RECIST 1.1 Per BICR

    Time to response (TTR) is defined as the time, in months, from randomization to the first objective documentation of PR or better assessed per BICR. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm.

    Time frame: From randomization untill disease progression or death, whichever occurs first (up to approximately 61 months)

  6. Progression Free Survival (PFS) by RECIST 1.1 Per Investigator Assessment

    Progression-Free Survival then (PFS) is defined as the time between the date of randomization and the date of first documented disease progression, based on Investigator assessments (per RECIST v1.1), or death due to any cause, whichever occurs first Calculated using Kaplan-Meier estimates. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

    Time frame: From randomization untill disease progression or death, whichever occurs first (up to approximately 61 months)

  7. Objective Response Rate (ORR) by RECIST 1.1 Per Investigator Assessment

    ORR is defined as the percentage of participants whose best overall response (BOR) is either CR or PR by investigator assessment per response evaluation criteria in solid tumors (RECIST) v1.1. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

    Time frame: From randomization untill disease progression or death, whichever occurs first (up to approximately 61 months)

  8. Duration of Response (DOR) by RECIST 1.1 Per Investigator Assessment

    Duration of objective response (DoR) is defined as the time between the date of first confirmed response (CR or PR) to the date of the first documented tumor progression (per RECIST 1.1) per investigator assessment, or death due to any cause, whichever occurs first. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

    Time frame: From randomization untill disease progression or death, whichever occurs first (up to approximately 61 months)

  9. Time to Response (TTR) by RECIST 1.1 Per Investigator Assessment

    Time to response (TTR) is defined as the time, in months, from randomization to the first objective documentation of PR or better assessed per investigator assessment. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

    Time frame: From randomization untill disease progression or death, whichever occurs first (up to approximately 61 months)

  10. Time to Death or Distant Metastases (TDDM)

    Time to Death or Distant Metastases (TDDM) is defined as the time from the date of randomization until the first date of distant metastasis or death in the absence of distant metastasis based on Kaplan-Meier estimates. Distant metastasis is defined as any new lesion that is outside of the thorax (except for heart) according to RECIST 1.1, as assessed by the Investigator.

    Time frame: From randomization until metastases or death, whichever occurs first (up to approximately 61 months)

  11. Number of Participants With Adverse Events (AEs), Serious AEs and Select AEs

    An Adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation patient administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease temporarily associated with the use of medicinal product, whether or not considered related to the investigational medicinal product. A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose results in death, is life-threatening (defined as an event in which the subject was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe), requires inpatient hospitalization or causes prolongation of existing hospitalization.

    Time frame: From first dose (Day 1) till 30 days after the last dose (up to approximately 19 months)

  12. Change From Baseline in Non-small Cell Lung Cancer (NSCLC)-Symptom Assessment Questionnaire (SAQ) Total Score at Week 48

    The NSCLC-SAQ is a questionnaire used in clinical trials to understand how non-small cell lung cancer (NSCLC) affects your daily life and well-being. It has 7 questions that ask about your symptoms over the past 7 days, including cough, pain, shortness of breath, fatigue, and appetite loss. The total scores from the questionnaire range from 0 to 20. A higher score means you have more severe symptoms and are feeling worse, which is a bad outcome. A lower score means you have fewer symptoms and are feeling better, which is a good outcome.

    Time frame: Baseline (Day 1) and Week 48

07

Results

Posted Jul 24, 2025

Participant flow

Participant flow — Overall Study
MilestoneArm A:Nivo + CCRT/Nivo + IpiArm B: Nivo + CCRT/NivoArm C: CCRT/Durva
Started287320318
Completed103138144
Not completed184182174

Outcome measures

PrimaryArm A Vs Arm C - Progression-Free Survival (PFS) by RECIST 1.1 Per Blinded Independent Central Review (BICR)

Progression-Free Survival then (PFS) is defined as the time between the date of randomization and the date of first documented disease progression, based on BICR assessments (per RECIST v1.1), or death due to any cause, whichever occurs first based on Kaplan-Meier estimates. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

Time frame:
From randomization untill disease progression or death, whichever occurs first (up to approximately 53 months)
Reported as:
Median · months
Arm A Vs Arm C - Progression-Free Survival (PFS) by RECIST 1.1 Per Blinded Independent Central Review (BICR)
monthsArm A:Nivo + CCRT/Nivo + IpiArm C: CCRT/Durva
Arm A Vs Arm C - Progression-Free Survival (PFS) by RECIST 1.1 Per Blinded Independent Central Review (BICR)16.69 (12.58 to 21.98)15.64 (13.67 to 19.75)
Statistical analysis
  • Arm A:Nivo + CCRT/Nivo + Ipi vs Arm C: CCRT/Durva · Cox proportional hazards model · p = 0.6460 · Hazard ratio (hr): 0.95 · 96% CI 0.77 to 1.19
SecondaryOverall Survival (OS)

Overall Survival (OS) for all randomized participants is the time between randomization and the date of death from any cause based on Kaplan-Meier estimates. For participants who are alive, their survival time was censored at the last date that they were known to be alive. OS was censored for participants at the date of randomization if they had no follow-up.

Time frame:
From randomization untill death (up to approximately 61 months)
Reported as:
Median · months
Overall Survival (OS)
monthsArm A:Nivo + CCRT/Nivo + IpiArm B: Nivo + CCRT/NivoArm C: CCRT/Durva
Overall Survival (OS)34.60 (26.81 to NA)39.49 (33.48 to NA)39.79 (30.92 to NA)
Statistical analysis
  • Arm A:Nivo + CCRT/Nivo + Ipi vs Arm C: CCRT/Durva · Hazard ratio (hr): 1.10 · 95% CI 0.87 to 1.41
  • Arm B: Nivo + CCRT/Nivo vs Arm C: CCRT/Durva · Hazard ratio (hr): 0.96 · 95% CI 0.75 to 1.22
  • Arm A:Nivo + CCRT/Nivo + Ipi vs Arm B: Nivo + CCRT/Nivo · Hazard ratio, log: 1.16 · 95% CI 0.91 to 1.48
SecondaryArm B Vs Arm C and Arm A Vs Arm B- Progression-Free Survival (Irrespective of Subsequent Therapy) by RECIST 1.1 Per Blinded Independent Central Review (BICR)

Progression-Free Survival (PFS) is defined as the time between the date of randomization and the date of first documented disease progression, based on BICR assessments (per RECIST v1.1), or death due to any cause, whichever occurs first based on Kaplan-Meier estimates. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

Time frame:
From randomization untill disease progression or death, whichever occurs first (up to approximately 61 months)
Reported as:
Median · months
Arm B Vs Arm C and Arm A Vs Arm B- Progression-Free Survival (Irrespective of Subsequent Therapy) by RECIST 1.1 Per Blinded Independent Central Review (BICR)
monthsArm A:Nivo + CCRT/Nivo + IpiArm B: Nivo + CCRT/NivoArm C: CCRT/Durva
Arm B Vs Arm C and Arm A Vs Arm B- Progression-Free Survival (Irrespective of Subsequent Therapy) by RECIST 1.1 Per Blinded Independent Central Review (BICR)16.82 (12.58 to 22.05)17.38 (14.09 to 22.14)15.67 (13.77 to 20.83)
Statistical analysis
  • Arm B: Nivo + CCRT/Nivo vs Arm C: CCRT/Durva · Hazard ratio (hr): 0.85 · 95% CI 0.69 to 1.05
  • Arm A:Nivo + CCRT/Nivo + Ipi vs Arm B: Nivo + CCRT/Nivo · Hazard ratio (hr): 1.15 · 95% CI 0.93 to 1.42
SecondaryObjective Response Rate (ORR) by BICR

Objective Response Rate (ORR) is defined as the percentage of participants whose best overall response (BOR) is either CR or PR by blinded independent central review (BICR) per response evaluation criteria in solid tumors (RECIST) v1.1. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

Time frame:
From randomization untill disease progression or death, whichever occurs first (up to approximately 61 months)
Reported as:
Number · percentage of participants
Objective Response Rate (ORR) by BICR
percentage of participantsArm A:Nivo + CCRT/Nivo + IpiArm B: Nivo + CCRT/NivoArm C: CCRT/Durva
Objective Response Rate (ORR) by BICR67.6 (61.8 to 73.0)72.2 (66.9 to 77.0)64.5 (58.9 to 69.7)
Statistical analysis
  • Arm A:Nivo + CCRT/Nivo + Ipi vs Arm C: CCRT/Durva · Difference in orr: 3.2 · 95% CI -4.1 to 10.6
  • Arm B: Nivo + CCRT/Nivo vs Arm C: CCRT/Durva · Difference in orr: 7.8 · 95% CI 0.7 to 14.8
  • Arm A:Nivo + CCRT/Nivo + Ipi vs Arm B: Nivo + CCRT/Nivo · Difference in orr: -4.7 · 95% CI -11.8 to 2.5
SecondaryDuration of Response (DoR) by RECIST 1.1 Per BICR

Duration of objective response (DoR) is defined as the time between the date of first confirmed response (CR or PR) to the date of the first documented tumor progression (per RECIST 1.1) per BICR assessment, or death due to any cause, whichever occurs first. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

Time frame:
From randomization untill disease progression or death, whichever occurs first (up to approximately 61 months)
Reported as:
Median · months
Duration of Response (DoR) by RECIST 1.1 Per BICR
monthsArm A:Nivo + CCRT/Nivo + IpiArm B: Nivo + CCRT/NivoArm C: CCRT/Durva
Duration of Response (DoR) by RECIST 1.1 Per BICR25.76 (2.1 to 47.9)31.84 (1.6 to 44.3)25.17 (1.0 to 44.3)
SecondaryTime to Response (TTR) by RECIST 1.1 Per BICR

Time to response (TTR) is defined as the time, in months, from randomization to the first objective documentation of PR or better assessed per BICR. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm.

Time frame:
From randomization untill disease progression or death, whichever occurs first (up to approximately 61 months)
Reported as:
Median · months
Time to Response (TTR) by RECIST 1.1 Per BICR
monthsArm A:Nivo + CCRT/Nivo + IpiArm B: Nivo + CCRT/NivoArm C: CCRT/Durva
Time to Response (TTR) by RECIST 1.1 Per BICR2.92 (0.9 to 22.2)2.96 (1.3 to 41.9)2.92 (1.2 to 24.9)
SecondaryProgression Free Survival (PFS) by RECIST 1.1 Per Investigator Assessment

Progression-Free Survival then (PFS) is defined as the time between the date of randomization and the date of first documented disease progression, based on Investigator assessments (per RECIST v1.1), or death due to any cause, whichever occurs first Calculated using Kaplan-Meier estimates. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

Time frame:
From randomization untill disease progression or death, whichever occurs first (up to approximately 61 months)
Reported as:
Median · months
Progression Free Survival (PFS) by RECIST 1.1 Per Investigator Assessment
monthsArm A:Nivo + CCRT/Nivo + IpiArm B: Nivo + CCRT/NivoArm C: CCRT/Durva
Progression Free Survival (PFS) by RECIST 1.1 Per Investigator Assessment16.82 (13.83 to 20.40)17.71 (13.83 to 24.71)16.53 (13.77 to 19.38)
Statistical analysis
  • Arm A:Nivo + CCRT/Nivo + Ipi vs Arm C: CCRT/Durva · Hazard ratio (hr): 1.00 · 95% CI 0.82 to 1.23
  • Arm B: Nivo + CCRT/Nivo vs Arm C: CCRT/Durva · Hazard ratio (hr): 0.86 · 95% CI 0.70 to 1.05
  • Arm A:Nivo + CCRT/Nivo + Ipi vs Arm B: Nivo + CCRT/Nivo · Hazard ratio (hr): 1.17 · 95% CI 0.95 to 1.44
SecondaryObjective Response Rate (ORR) by RECIST 1.1 Per Investigator Assessment

ORR is defined as the percentage of participants whose best overall response (BOR) is either CR or PR by investigator assessment per response evaluation criteria in solid tumors (RECIST) v1.1. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

Time frame:
From randomization untill disease progression or death, whichever occurs first (up to approximately 61 months)
Reported as:
Number · percentage of participants
Objective Response Rate (ORR) by RECIST 1.1 Per Investigator Assessment
percentage of participantsArm A:Nivo + CCRT/Nivo + IpiArm B: Nivo + CCRT/NivoArm C: CCRT/Durva
Objective Response Rate (ORR) by RECIST 1.1 Per Investigator Assessment61.3 (55.4 to 67.0)63.1 (57.6 to 68.4)57.9 (52.2 to 63.4)
Statistical analysis
  • Arm A:Nivo + CCRT/Nivo + Ipi vs Arm C: CCRT/Durva · Difference in orr: 3.5 · 95% CI -4.1 to 11.1
  • Arm B: Nivo + CCRT/Nivo vs Arm C: CCRT/Durva · Difference in orr: 5.4 · 95% CI -2.0 to 12.9
  • Arm A:Nivo + CCRT/Nivo + Ipi vs Arm B: Nivo + CCRT/Nivo · Difference in orr: -1.9 · 95% CI -9.5 to 5.6
SecondaryDuration of Response (DOR) by RECIST 1.1 Per Investigator Assessment

Duration of objective response (DoR) is defined as the time between the date of first confirmed response (CR or PR) to the date of the first documented tumor progression (per RECIST 1.1) per investigator assessment, or death due to any cause, whichever occurs first. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

Time frame:
From randomization untill disease progression or death, whichever occurs first (up to approximately 61 months)
Reported as:
Median · months
Duration of Response (DOR) by RECIST 1.1 Per Investigator Assessment
monthsArm A:Nivo + CCRT/Nivo + IpiArm B: Nivo + CCRT/NivoArm C: CCRT/Durva
Duration of Response (DOR) by RECIST 1.1 Per Investigator Assessment22.83 (0.0 to 47.4)33.18 (0.0 to 47.6)27.93 (0.0 to 46.5)
SecondaryTime to Response (TTR) by RECIST 1.1 Per Investigator Assessment

Time to response (TTR) is defined as the time, in months, from randomization to the first objective documentation of PR or better assessed per investigator assessment. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

Time frame:
From randomization untill disease progression or death, whichever occurs first (up to approximately 61 months)
Reported as:
Median · months
Time to Response (TTR) by RECIST 1.1 Per Investigator Assessment
monthsArm A:Nivo + CCRT/Nivo + IpiArm B: Nivo + CCRT/NivoArm C: CCRT/Durva
Time to Response (TTR) by RECIST 1.1 Per Investigator Assessment2.96 (1.9 to 25.2)2.92 (1.9 to 16.5)2.89 (1.4 to 22.1)
SecondaryTime to Death or Distant Metastases (TDDM)

Time to Death or Distant Metastases (TDDM) is defined as the time from the date of randomization until the first date of distant metastasis or death in the absence of distant metastasis based on Kaplan-Meier estimates. Distant metastasis is defined as any new lesion that is outside of the thorax (except for heart) according to RECIST 1.1, as assessed by the Investigator.

Time frame:
From randomization until metastases or death, whichever occurs first (up to approximately 61 months)
Reported as:
Median · months
Time to Death or Distant Metastases (TDDM)
monthsArm A:Nivo + CCRT/Nivo + IpiArm B: Nivo + CCRT/NivoArm C: CCRT/Durva
Time to Death or Distant Metastases (TDDM)30.65 (22.57 to NA)36.14 (25.86 to NA)30.36 (21.62 to 40.15)
Statistical analysis
  • Arm A:Nivo + CCRT/Nivo + Ipi vs Arm C: CCRT/Durva · Hazard ratio (hr): 0.97 · 95% CI 0.76 to 1.23
  • Arm B: Nivo + CCRT/Nivo vs Arm C: CCRT/Durva · Hazard ratio (hr): 0.83 · 95% CI 0.65 to 1.06
  • Arm A:Nivo + CCRT/Nivo + Ipi vs Arm B: Nivo + CCRT/Nivo · Hazard ratio (hr): 1.16 · 95% CI 0.91 to 1.49
SecondaryNumber of Participants With Adverse Events (AEs), Serious AEs and Select AEs

An Adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation patient administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease temporarily associated with the use of medicinal product, whether or not considered related to the investigational medicinal product. A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose results in death, is life-threatening (defined as an event in which the subject was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe), requires inpatient hospitalization or causes prolongation of existing hospitalization.

Time frame:
From first dose (Day 1) till 30 days after the last dose (up to approximately 19 months)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs), Serious AEs and Select AEs
ParticipantsArm A:Nivo + CCRT/Nivo + IpiArm B: Nivo + CCRT/NivoArm C: CCRT/Durva
ADVERSE EVENTS279315312
SERIOUS ADVERSE EVENTS155156136
GASTROINTESTINAL ADVERSE EVENT676054
HEPATIC ADVERSE EVENT555972
PULMONARY ADVERSE EVENT879255
RENAL ADVERSE EVENT251632
SKIN ADVERSE EVENT111115115
HYPERSENSITIVITY/INFUSION REACTION18179
SecondaryChange From Baseline in Non-small Cell Lung Cancer (NSCLC)-Symptom Assessment Questionnaire (SAQ) Total Score at Week 48

The NSCLC-SAQ is a questionnaire used in clinical trials to understand how non-small cell lung cancer (NSCLC) affects your daily life and well-being. It has 7 questions that ask about your symptoms over the past 7 days, including cough, pain, shortness of breath, fatigue, and appetite loss. The total scores from the questionnaire range from 0 to 20. A higher score means you have more severe symptoms and are feeling worse, which is a bad outcome. A lower score means you have fewer symptoms and are feeling better, which is a good outcome.

Time frame:
Baseline (Day 1) and Week 48
Reported as:
Mean · Score on a Scale
Change From Baseline in Non-small Cell Lung Cancer (NSCLC)-Symptom Assessment Questionnaire (SAQ) Total Score at Week 48
Score on a ScaleArm A:Nivo + CCRT/Nivo + IpiArm B: Nivo + CCRT/NivoArm C: CCRT/Durva
Change From Baseline in Non-small Cell Lung Cancer (NSCLC)-Symptom Assessment Questionnaire (SAQ) Total Score at Week 48-0.60 ± 3.260-0.91 ± 3.507-0.89 ± 3.731

Adverse events

Collected over All-cause mortality was collected from randomization until death due to any cause (up to approximately 61 months). Serious and Non-serious AEs were collected from first dose (Day 1) till 30 days after the last dose (up to approximately 19 months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A:Nivo + CCRT/Nivo + Ipi132/287 (46%)180/282 (63.8%)273/282 (96.8%)
Arm B: Nivo + CCRT/Nivo132/320 (41.3%)181/318 (56.9%)310/318 (97.5%)
Arm C: CCRT/Durva132/318 (41.5%)145/317 (45.7%)307/317 (96.8%)
Most frequent serious events
Showing 10 of 267
Most frequent serious events
EventArm A:Nivo + CCRT/Nivo + IpiArm B: Nivo + CCRT/NivoArm C: CCRT/Durva
PneumoniaInfections and infestations33/28239/31829/317
PneumonitisRespiratory, thoracic and mediastinal disorders32/28232/31811/317
Radiation pneumonitisInjury, poisoning and procedural complications18/28215/31813/317
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)17/28212/31814/317
Immune-mediated lung diseaseRespiratory, thoracic and mediastinal disorders13/28210/3182/317
COVID-19Infections and infestations9/28211/3186/317
DyspnoeaRespiratory, thoracic and mediastinal disorders9/2829/3184/317
HaemoptysisRespiratory, thoracic and mediastinal disorders4/2825/31810/317
AnaemiaBlood and lymphatic system disorders6/2823/3189/317
OesophagitisGastrointestinal disorders1/2828/3184/317
Most frequent other events
Showing 10 of 64
Most frequent other events
EventArm A:Nivo + CCRT/Nivo + IpiArm B: Nivo + CCRT/NivoArm C: CCRT/Durva
AnaemiaBlood and lymphatic system disorders124/282132/318134/317
NauseaGastrointestinal disorders98/282104/318108/317
ConstipationGastrointestinal disorders82/28278/31889/317
CoughRespiratory, thoracic and mediastinal disorders82/28283/31887/317
Decreased appetiteMetabolism and nutrition disorders79/28264/31877/317
OesophagitisGastrointestinal disorders74/28281/31869/317
FatigueGeneral disorders60/28261/31877/317
PneumonitisRespiratory, thoracic and mediastinal disorders62/28276/31848/317
White blood cell count decreasedInvestigations65/28273/31863/317
PruritusSkin and subcutaneous tissue disorders65/28254/31851/317

Baseline characteristics

Age, Continuous
Age, Continuous(years)Arm A:Nivo + CCRT/Nivo + IpiArm B: Nivo + CCRT/NivoArm C: CCRT/DurvaTotal
Mean63.7 ± 8.9963.7 ± 8.5063.9 ± 9.1863.8 ± 8.88
Sex: Female, Male
Sex: Female, Male(Participants)Arm A:Nivo + CCRT/Nivo + IpiArm B: Nivo + CCRT/NivoArm C: CCRT/DurvaTotal
Female677679222
Male220244239703
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm A:Nivo + CCRT/Nivo + IpiArm B: Nivo + CCRT/NivoArm C: CCRT/DurvaTotal
Hispanic or Latino28323292
Not Hispanic or Latino155167157479
Unknown or Not Reported104121129354
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm A:Nivo + CCRT/Nivo + IpiArm B: Nivo + CCRT/NivoArm C: CCRT/DurvaTotal
American Indian or Alaska Native1001
Asian93119105317
Native Hawaiian or Other Pacific Islander0000
Black or African American54211
White182192204578
More than one race0000
Unknown or Not Reported65718
08

Study locations

183 sites
  • Local Institution - 0119
    La Jolla, California 92093, United States
  • Local Institution - 0207
    San Francisco, California 94115, United States
  • Local Institution - 0166
    San Francisco, California 94143, United States
  • Local Institution - 0129
    Lone Tree, Colorado 80124, United States
  • Local Institution - 0233
    Jacksonville, Florida 32207, United States
  • Local Institution - 0219
    Orlando, Florida 32804, United States
  • Local Institution - 0039
    Pensacola, Florida 32504, United States
  • Local Institution - 0125
    Atlanta, Georgia 30322, United States
  • Local Institution - 0165
    Augusta, Georgia 30912, United States
  • Local Institution - 0218
    Edgewood, Kentucky 41017, United States
  • Local Institution - 0108
    Bethesda, Maryland 20817, United States
  • Local Institution - 0116
    Traverse City, Michigan 49684, United States
  • Local Institution - 0053
    Cincinnati, Ohio 45220, United States
  • Local Institution - 0131
    Cincinnati, Ohio 45242, United States
  • Local Institution - 0188
    Cincinnati, Ohio 45267, United States
  • Local Institution - 0112
    Cleveland, Ohio 44106, United States
  • Local Institution - 0124
    Cleveland, Ohio 44106, United States
  • Local Institution - 0047
    Cleveland, Ohio 44109, United States
  • Local Institution - 0123
    Youngstown, Ohio 44501, United States
  • Local Institution - 0077
    Charleston, South Carolina 29414, United States
  • Local Institution - 0191
    Austin, Texas 78731, United States
  • Local Institution - 0079
    Bryan, Texas 77802, United States
  • Local Institution - 0130
    Dallas, Texas 75203, United States
  • Local Institution - 0071
    Burlington, Vermont 05405, United States
  • Local Institution - 0044
    CABA, Buenos Aires C1426ANZ, Argentina
  • Local Institution - 0045
    Río Cuarto, Córdoba Province 5800, Argentina
  • Local Institution - 0043
    Buenos Aires, Distrito Federal C1199ABB, Argentina
  • Local Institution - 0042
    Caba, Distrito Federal 1430, Argentina
  • Local Institution - 0031
    Darlinghurst, New South Wales 2010, Australia
  • Local Institution - 0134
    Gosford, New South Wales 2250, Australia
  • Local Institution - 0033
    Kingswood, New South Wales 2747, Australia
  • Local Institution - 0029
    Greenslopes, Queensland 4120, Australia
  • Local Institution - 0028
    Adelaide, South Australia 5000, Australia
  • Local Institution - 0224
    Ballarat Central, Victoria 3350, Australia
  • Local Institution - 0052
    Melbourne, Victoria 3004, Australia
  • Local Institution
    Melbourne, Victoria 3199, Australia
  • Local Institution - 0030
    Murdoch, Western Australia 6150, Australia
  • Local Institution - 0003
    Brussels, 1200, Belgium
  • Local Institution - 0001
    Ghent, 9000, Belgium
  • Local Institution - 0004
    Liège, 4000, Belgium
  • Local Institution - 0002
    Yvoir, B-5530, Belgium
  • Local Institution - 0038
    Ipatinga, Minas Gerais 35160-158, Brazil
  • Local Institution - 0234
    Ijuí, Rio Grande do Sul 98700-000, Brazil
  • Local Institution - 0034
    Porto Alegre, Rio Grande do Sul 91350-200, Brazil
  • Local Institution - 0037
    Blumenau, Santa Catarina 89010-340, Brazil
  • Local Institution - 0036
    Barretos, São Paulo 14784-400, Brazil
  • Local Institution - 0035
    Rio de Janeiro, 20230-130, Brazil
  • Local Institution - 0127
    Kingston, Ontario K7L 2V7, Canada
  • Local Institution - 0078
    Oshawa, Ontario L1G 2B9, Canada
  • Local Institution - 0237
    Chicoutimi, Quebec G7H 5H6, Canada
  • Local Institution - 0126
    Québec, Quebec G1V 4G5, Canada
  • Local Institution - 0070
    Rimouski, Quebec G5L 5T1, Canada
  • Local Institution - 0092
    Trois-Rivières, Quebec G8Z 3R9, Canada
  • Local Institution - 0041
    Santiago, Santiago Metropolitan 8420383, Chile
  • Local Institution - 0040
    Viña del Mar, Valparaiso 2520598, Chile
  • Local Institution - 0146
    Beijing, BEI 100142, China
  • Local Institution - 0149
    Chongqing, Chongqing Municipality 400030, China
  • Local Institution - 0179
    Fuzhou, Fujian 350000, China
  • Local Institution - 0164
    Xiamen, Fujian 361003, China
  • Local Institution - 0192
    Guiyang, Guizhou 550002, China
  • Local Institution - 0147
    Hankou, Hubei 430023, China
  • Local Institution - 0148
    Wuhan, Hubei 210000, China
  • Local Institution - 0150
    Wuhan, Hubei 430060, China
  • Local Institution - 0154
    Changsha, Hunan 410011, China
  • Local Institution - 0139
    Nanjing, Jiangsu 210009, China
  • Local Institution - 0178
    Nanchang, Jiangxi 330006, China
  • Local Institution - 0170
    Changchun, Jilin 130012, China
  • Local Institution - 0183
    Changchun, Jilin 130021, China
  • Local Institution - 0180
    Gongzhuling, Jilin 132000, China
  • Local Institution - 0138
    Jinan, Shandong 250117, China
  • Local Institution - 0145
    Shanghai, Shanghai Municipality 200443, China
  • Local Institution - 0186
    Chengdu, Sichuan 610041, China
  • Local Institution - 0189
    Chengdu, Sichuan 610041, China
  • Local Institution - 0140
    Hangzhou, Zhejiang 310000, China
  • Local Institution - 0184
    Linhai, Zhejiang 317000, China
  • Local Institution - 0086
    Bordeaux, 33076, France
  • Local Institution - 0087
    Dijon, 21000, France
  • Local Institution - 0081
    Lyon, 69008, France
  • Local Institution - 0082
    Montpellier, 34070, France
  • Local Institution - 0084
    Nantes, 44000, France
  • Local Institution - 0227
    Paris, 75018, France
  • Local Institution - 0091
    Paris, 75020, France
  • Local Institution - 0083
    Paris, 75248, France
  • Local Institution - 0090
    Paris, 75679, France
  • Local Institution - 0089
    Tours, 37044, France
  • Local Institution - 0060
    Berlin, 14165, Germany
  • Local Institution - 0063
    Essen, 45136, Germany
  • Local Institution - 0076
    Großhansdorf, 22927, Germany
  • Local Institution - 0101
    Hamm, 59063, Germany
  • Local Institution - 0073
    Heidelberg, 69126, Germany
  • Local Institution - 0061
    Immenhausen, 34376, Germany
  • Local Institution - 0062
    Kempten, 87439, Germany
  • Local Institution - 0075
    Löwenstein, 74245, Germany
  • Local Institution - 0109
    Mainz, 55131, Germany
  • Local Institution - 0072
    Stuttgart, 70376, Germany
  • Local Institution - 0161
    Athens, 115 22, Greece
  • Local Institution - 0135
    Athens, 11527, Greece
  • Local Institution - 0136
    Larissa, 41110, Greece
  • Local Institution - 0162
    N.Kifissia, 14564, Greece
  • Local Institution - 0024
    Dublin, Dublin, Ireland

Showing the first 100 of 183 sites across 27 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Peters S, Tan DSW, Gerber DE, Urbanic J, Ramalingam S, Yu J, Xing L, Rittmeyer A, Ciuleanu TE, de Menezes J, Kim HR, Rojas C, Syrigos K, Hayashi H, Haridass A, Cortinovis D, Bruno D, Kimmich M, Calles A, Nathani R, Pudussery G, Yang L, De Ruysscher D. Nivolumab plus chemoradiotherapy followed by nivolumab with or without ipilimumab for untreated locally advanced stage III NSCLC: a randomized phase 3 trial. Nat Cancer. 2026 May 13. doi: 10.1038/s43018-026-01161-y. Online ahead of print. PubMed 42129521 ↗
  • De Ruysscher D, Ramalingam S, Urbanic J, Gerber DE, Tan DSW, Cai J, Li A, Peters S. CheckMate 73L: A Phase 3 Study Comparing Nivolumab Plus Concurrent Chemoradiotherapy Followed by Nivolumab With or Without Ipilimumab Versus Concurrent Chemoradiotherapy Followed by Durvalumab for Previously Untreated, Locally Advanced Stage III Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2022 May;23(3):e264-e268. doi: 10.1016/j.cllc.2021.07.005. Epub 2021 Jul 19. PubMed 34489161 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2019 to primary completion in Mar 2024, 53 months.

Results were first posted in Jul 2025, 1 year 4 months after primary completion.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 53 months is above that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 18, 2019
First posted
Jul 19, 2019
StartActual
Oct 8, 2019
Primary completionActual
Mar 22, 2024
CompletionActual
Nov 26, 2024
Results first posted
Jul 24, 2025
Last update
Jul 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04026412
Responsible party
Sponsor
First posted
Jul 19, 2019
Start date
Oct 8, 2019
Primary completion
Mar 22, 2024
Completion
Nov 26, 2024
Results posted
Jul 24, 2025
Last update
Jul 24, 2025

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nivolumab · Ipilimumab

Start the discussion